Interestingly, the presented correlation between PD-1 expression and disease severity, as well as the development of complications like PIMS, may serve both as biomarkers for disease progression, but also as possible therapeutic targets by anti-PD-1 drugs, which have been used in various conditions, including cancers and few infectious diseases [14]. This evidence concerns the gene PDCD1 and cancer.